Articles
What Are IDEAs Made Of: The SWOT

What Are IDEAs Made Of: The SWOT

Mike Rea is back for the second piece in the What Are IDEAs Made Of (WAIMO) series, where he takes a fresh look at pharma marketing and challenges our current perceptions. This time it’s the good old SWOT chart that gets the WAIMO treatment. The SWOT is useless as a tool. You already know why. A "strength" in one context is a "weakness" in another. So, the context counts. You know that...

Articles
Interferons: a viable alternative to antibiotics?

Interferons: a viable alternative to antibiotics?

In response to two recent articles looking at antibiotic de-escalation and antimicrobial peptides, Richard Müller explores a third option for dealing with antibiotic resistance and asks whether interferons should play a much larger role in the West. As we all know the macrophage plays an essential role in initiation and maintenance of the immune response, and so in light of the increased...

Articles
'Twas the night before Christmas (US Senate style)

'Twas the night before Christmas (US Senate style)

As Christmas fast approaches and the healthcare reform debate reaches a head in the US Senate, Paul Tunnah pokes fun at proceedings in a very festive way. Well, another year is almost over and for those of us who celebrate it Christmas is only a couple of days away now. As many take some hard earned rest, the subject of healthcare reform is keeping the Senate very busy...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. AbbVie's Cerevel takeover delivers Parkinson's approval
  2. FDA clears first drug for MCT8 deficiency
  3. Novartis taps China's Abogen for autoimmunity TCE
  4. AZ takes stake in Summit Therapeutics in $2bn deal
  5. PhRMA hires ex-House Majority Leader Eric Cantor as its CEO

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more